|Bid||21.90 x 1000|
|Ask||22.44 x 1000|
|Day's Range||21.73 - 22.48|
|52 Week Range||18.18 - 27.35|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||109.32|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Best of all, you don't need to have Warren Buffett's pocketbook to build wealth on Wall Street. The rise of commission-free trading platforms and the removal of minimum deposit amounts by most brokerages means $100 is more than enough to begin or further your trek to financial freedom. As you're about to see, healthcare stocks are a wise place to put your money to work.
Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.
Exelixis (NASDAQ: EXEL) continues to grow sales of its cancer drug Cabometyx, thanks in large part to data showing the drug works well in combination with Bristol Myers Squibb's (NYSE: BMY) Opdivo. In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss the biotech's first-quarter results and why the increased revenue failed to translate into an as impressive increase in earnings. Brian Orelli: Cancer drug company Exelixis reported revenue growth in the first quarter, but it's ramping up R&D, which hurt the bottom line.